Entrada Therapeutics (TRDA) Assets (2020 - 2026)
Entrada Therapeutics (TRDA) posted quarterly Assets of $335.5 million for Q1 2026, down 31.03% year-over-year from $486.5 million in Q1 2025, and down 11.09% quarter-over-quarter from $377.4 million in Q4 2025.
Entrada Therapeutics (TRDA) Assets (2020 - 2026) Analysis & Trends
Entrada Therapeutics' Assets history runs 7 years deep, the most recent figure standing at $335.5 million for Q1 2026.
- In Q1 2026, Assets fell 31.03% year-over-year to $335.5 million; the TTM figure through Mar 2026 stood at $335.5 million (down 31.03% YoY), while the FY2025 annual figure was $377.4 million, down 28.3% from the prior year.
- Assets for Q1 2026 stood at $335.5 million, down from $377.4 million in the prior quarter.
- The five-year high for Assets was $582.0 million in Q2 2024, with the low at $252.1 million in Q4 2022.
- The 5-year median for Assets is $469.2 million (2023), against an average of $429.3 million.
- The sharpest annual moves came in 2022 and 2026: Assets jumped 107.31% in 2022, then tumbled 31.03% in 2026.
- Entrada Therapeutics' Assets stood at $252.1 million in 2022, then jumped by 86.15% to $469.2 million in 2023, then gained by 12.18% to $526.3 million in 2024, then declined by 28.3% to $377.4 million in 2025, then decreased by 11.09% to $335.5 million in 2026.
- Business Quant data shows TRDA's Assets at $335.5 million in Q1 2026, $377.4 million in Q4 2025, and $412.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Entrada Therapeutics | 290.47 Mn | 290.47 Mn | - | 298.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 298.88 Mn |
| Mar 31, 2026 | 335.52 Mn |
| Dec 31, 2025 | 377.38 Mn |
| Sep 30, 2025 | 412.90 Mn |
| Jun 30, 2025 | 448.78 Mn |
| Mar 31, 2025 | 486.48 Mn |
| Dec 31, 2024 | 526.32 Mn |
| Sep 30, 2024 | 554.59 Mn |
| Jun 30, 2024 | 581.96 Mn |
| Mar 31, 2024 | 510.84 Mn |
| Dec 31, 2023 | 469.19 Mn |
| Sep 30, 2023 | 485.03 Mn |
| Jun 30, 2023 | 493.98 Mn |
| Mar 31, 2023 | 475.57 Mn |
| Dec 31, 2022 | 252.06 Mn |
| Sep 30, 2022 | 274.46 Mn |
| Jun 30, 2022 | 295.92 Mn |
| Mar 31, 2022 | 316.70 Mn |
| Dec 31, 2021 | 305.83 Mn |
| Sep 30, 2021 | 132.40 Mn |